'The lung pain was so severe, I wonder if I’ll ever fully recover.'
After that, I started to trend better. On Friday, May 1, I finally got tested for COVID-19, and by then my result was negative.
Since then, I’ve built up my endurance, but it’s far from where it was in early March. Last week, I was able to jog 20 minutes straight; I didn’t turn on mypace function, but I would be shocked if I went faster than 10 minutes a mile. It felt pretty bad, and my lungs hurt for several days afterward. Three months ago, a 20-minute jog would have been a morning shakeout before an afternoon workout. Now, it’s the big athletic event of my week.
I’m privileged to worry about my recreational sports when people are worrying for their lives. This illness has shown me how much I take for granted the ability to breathe freely. The last several weeks have reminded me that Black people can't breathe freely in America, whether they are under the knee of the police or disproportionately dying of COVID-19.
Early on, the message to young people was that your grandma would get sick from COVID-19, but you’d just get a cold. As a 28-year-old runner who might have permanent lung damage, I can tell you that’s not true.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
After Pakistan's lockdown gamble, COVID-19 cases surgeFour weeks ago, with its most important festival coming up and millions of people facing starvation as economic activity dwindled, Pakistan lifted a two-month-long coronavirus lockdown.
続きを読む »
Novavax's stock soars after DoD contract to make its COVID-19 vaccine candidateShares of Novavax Inc. soared 14% in premarket trading Friday, after the biotechnology company said it was awarded a contract by the U.S. Department of Defense to manufacture its NVX‑CoV2373 COVID-19 vaccine candidate. The DoD has agreed to provide Novavax with up to $60 million to fund the production of several components of the potential vaccine in the U.S. As part of the contract, announced late Thursday, Novavax agreed to delivery in 2020 10 million doses of NVX‑CoV2373 for DoD that could be used in phase 2/3 clinical trials, or under an Emergency Use Authorization if approved by the Food and Drug Administration. On Friday, J.P. Morgan analyst analyst Eric Joseph upgraded Novavax's stock to neutral from underweight, while reiterating his $46 stock price target, saying current share price levels reflect the potential promise for the COVID-19 vaccine program. The stock has rocketed more than 11-fold year to date through Thursday (up 1,022%), while the S&P 500 has slipped 3.7%.
続きを読む »
Bombardier to cut 2,500 aviation jobs as COVID-19 hurts salesCanadian business jet maker Bombardier Inc said on Friday it would cut 2,500 jobs at its aviation unit and take a related charge of $40 million this year, as the COVID-19 pandemic hurts sales.
続きを読む »
COVID-19 Is a Symptom of a Bigger Problem: Our Planet’s Ailing HealthOn World Environment Day, Inger Andersen and Johan Rockström explain how the COVID-19 pandemic is a sign of bigger problems with the Earth.
続きを読む »
Because of COVID-19 pandemic Navy to start 'safe haven' ports of call for its shipsIn an effort to keep a 'COVID-free bubble' for its sailors at sea during the pandemic, the Navy will only allow ports of call at a select number of Navy bases around the world that will serve as 'safe havens.'
続きを読む »